Unusual Options Activity In Corning (GLW)
10199 $GLW APR 17th 2025 48.00 CALLS BOUGHT@ 1.94 vs Open Interest of 263 for a total of $1978606 on the BULL side
10199 $GLW APR 17th 2025 48.00 CALLS BOUGHT@ 1.94 vs Open Interest of 263 for a total of $1978606 on the BULL side
PG&E Corp. is a holding company, which engages in generation, transmission, and distribution of electricity and natural gas to customers.
Intuit Inc. is an American business software company that specializes in financial software. The company is headquartered in Mountain View, California, and the CEO is Sasan Goodarzi. Intuit’s products include the tax preparation application TurboTax, personal finance app Mint, the small business accounting program QuickBooks, the credit monitoring service Credit Karma, and email marketing platform Mailchimp.
3427 $CVX JUN 20th 2025 160.00 PUTS BOUGHT@ 5.2 vs Open Interest of 2655 for a total of $1787240 on the BEAR side
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
CVS Health Corporation is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider, among many other brands.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.